The drug you are referring to is called sacubitril/valsartan (trade name Entresto). It is a combination drug that consists of sacubitril, which inhibits neprilysin (NEP), and valsartan, which is an angiotensin receptor blocker (ARB) that inhibits the conversion of angiotensin II (ACE 1) to angiotensin 1-7 (ACE 2).
Sacubitril/valsartan is used for the treatment of heart failure with reduced ejection fraction, as it has been shown to reduce the risk of hospitalization and death compared to standard therapy. By inhibiting NEP, sacubitril increases the levels of natriuretic peptides, which are natural hormones that help regulate blood pressure and fluid balance. By inhibiting ACE 1 and promoting the accumulation of ACE 2, valsartan reduces the production of angiotensin II, a potent vasoconstrictor that can contribute to heart failure. Overall, sacubitril/valsartan improves cardiac function and reduces symptoms in patients with heart failure with reduced ejection fraction.